Barclays PLC grew its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 84.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,628 shares of the pharmaceutical company's stock after purchasing an additional 22,689 shares during the period. Barclays PLC's holdings in GSK were worth $1,678,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Indiana Trust & Investment Management Co grew its holdings in GSK by 200.0% in the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company's stock worth $25,000 after buying an additional 500 shares in the last quarter. Crews Bank & Trust bought a new stake in GSK during the fourth quarter worth approximately $26,000. ST Germain D J Co. Inc. lifted its position in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Sierra Ocean LLC bought a new stake in shares of GSK during the 4th quarter worth $32,000. Finally, Parkside Financial Bank & Trust grew its holdings in shares of GSK by 470.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after acquiring an additional 818 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently weighed in on GSK shares. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. BNP Paribas assumed coverage on GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Finally, Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.
Read Our Latest Report on GSK
GSK Stock Down 0.5 %
Shares of NYSE:GSK traded down $0.20 on Monday, reaching $38.87. The company had a trading volume of 2,819,022 shares, compared to its average volume of 4,736,586. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $80.20 billion, a P/E ratio of 24.45, a P/E/G ratio of 1.12 and a beta of 0.51. The stock has a 50-day moving average price of $37.68 and a 200 day moving average price of $36.00. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93.
GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter last year, the company posted $0.43 earnings per share. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities analysts expect that GSK plc will post 4.14 EPS for the current year.
GSK Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This represents a $1.69 dividend on an annualized basis and a yield of 4.34%. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio is 86.60%.
GSK Company Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Stories
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
